Aiello Joshua 4
4 · Orchestra BioMed Holdings, Inc. · Filed Feb 13, 2026
Research Summary
AI-generated summary of this filing
Orchestra BioMed (OBIO) Accounting Officer Joshua Aiello Receives Option Award
What Happened
Joshua Aiello, Principal Accounting Officer at Orchestra BioMed (OBIO), was granted 70,000 derivative securities reported as an award on February 12, 2026. The Form 4 lists the acquisition price as $0.00 (derivative award), so no cash was paid in this transaction. This is an equity-compensation award (stock options or similar), not an open‑market purchase or sale.
Key Details
- Transaction date: February 12, 2026; Form 4 filed Feb 13, 2026 (reporting timely).
- Reported acquisition: 70,000 shares (derivative award) at $0.00 reported price.
- Shares/ownership after transaction: Not specified in the provided filing excerpt.
- Vesting (per footnote): 25% vest on Feb 12, 2027; the remaining 75% vest in equal installments every three months starting May 12, 2027, subject to continuous service.
- No indication in the filing that any shares were immediately sold or that a 10b5-1 plan, gift, or tax-withholding event applied.
Context
This was a standard equity award to an executive — a compensation event rather than a market trade — and the award vests over time, which is typical for retaining employees. Because this is a derivative grant (options/awards), it does not by itself reflect an immediate buy or sell signal.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-02-12+70,000→ 70,000 totalExercise: $3.82Exp: 2036-02-12→ Common Stock (70,000 underlying)
Footnotes (1)
- [F1]The stock options will vest as follows: (i) 25% of the stock options will vest on February 12, 2027 (the "Vesting Commencement Date") and (ii) the remaining 75% stock options will vest in equal installments every three months on the same day of the month as the Vesting Commencement Date, starting on May 12, 2027, subject to the Reporting Person's continuous service through such dates.